BAXTER INTERNATIONAL INC.

Net Sales Periods Ending June 30, 2014 and 2013 (unaudited) (\$ in millions)

	Q2 2014	Q2 2013	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2014	YTD 2013	% Growth @	% Growth @ Constant Rates
	2014	2010	7 totaar ratoo	Constant Rates	2017	2010	7 totaal 1 tatoo	Jonetant Rates
BioScience								
United States	\$835	\$782	7%	7%	\$1,659	\$1,555	7%	7%
International	916	856	7%	5%	1,700	1,613	5%	5%
Total BioScience	\$1,751	\$1,638	7%	6%	\$3,359	\$3,168	6%	6%
Medical Products								
United States	\$897	\$764	17%	17%	\$1,733	\$1,473	18%	18%
International	1,616	1,267	28%	28%	3,123	2,476	26%	28%
Total Medical Products ¹	\$2,513	\$2,031	24%	24%	\$4,856	\$3,949	23%	24%
Baxter International Inc.								
United States	\$1,732	\$1,546	12%	12%	\$3,392	\$3,028	12%	12%
International	2,532	2,123	19%	19%	4,823	4,089	18%	19%
Total Baxter ¹	\$4,264	\$3,669	16%	16%	\$8,215	\$7,117	15%	16%

¹ Includes Gambro net sales of \$408 million in the second quarter of 2014 and \$808 million for the six months ended June 30, 2014. Medical Products net sales excluding Gambro grew 4% at both actual rates and constant rates during the second quarter of 2014. Total Baxter net sales excluding Gambro grew 5% at both actual rates and constant rates during the second quarter of 2014. Medical Products net sales excluding Gambro grew 3% at actual rates and 4% at constant rates for the six months ended June 30, 2014. Total Baxter net sales excluding Gambro grew 4% at actual rates and 5% at constant rates for the six months ended June 30, 2014.